Menopausal symptoms negatively impact quality of life in breast cancer survivors. The paucity of data on the impact of Menopausal Hormone Therapy (MHT) on oncological outcomes in these patients limits informed clinical discussion. Defining the risk of cancer recurrence with MHT is central to the appraisal of risk/benefit, particularly with low-risk disease (based on genomic profile). The aim of this review is to summarize the current data evaluating MHT in breast cancer patients. A systematic review of the literature was performed to evaluate the impact of MHT on oncological outcomes in breast cancer survivors. Three major databases (PubMed, EMBASE and Medline) were searched. The review included all prospective studies published in English. Four randomized control trials and four non-randomized prospective studies were identified. An increase in breast cancer recurrence with MHT was observed in the early randomized trials whilst no increased risk of recurrence was reported in the observational studies. There remains a need to quantify MHT-related recurrence risk in patients with molecularly favorable disease.
更年期症状对乳腺癌幸存者的生活质量产生负面影响。关于绝经激素治疗（MHT）对这类患者肿瘤学结局影响的数据匮乏，限制了临床决策的充分讨论。评估MHT相关癌症复发风险是权衡治疗利弊的核心，尤其对于低风险疾病（基于基因组特征）。本综述旨在总结当前评估乳腺癌患者使用MHT的研究数据。通过系统文献回顾，评估MHT对乳腺癌幸存者肿瘤学结局的影响，检索了三大数据库（PubMed、EMBASE和Medline），纳入所有以英文发表的前瞻性研究。共识别出四项随机对照试验和四项非随机前瞻性研究。早期随机试验观察到MHT会增加乳腺癌复发风险，而观察性研究未报告复发风险增加。目前仍需量化分子特征良好患者中MHT相关的复发风险。
肿瘤(癌症)患者之家